Galectin Therapeutics GALT
NASDAQ GALT
$3.29 -0.09 (-2.66%)
At close: Nov 11, 2026 · 4:00 PM EST

Galectin Therapeutics (GALT) Equity Income (2014)

Updated

Galectin Therapeutics (GALT) recorded Equity Income of -$10,000 in Q4 2014.

Analysis

Galectin Therapeutics (GALT) Equity Income (2014) Analysis & Trends

For FY2014, Galectin Therapeutics reported Equity Income of -$400,000.

  • Per Business Quant, the preceding three quarters came in at -$53,000 (Q3 2014), -$67,000 (Q2 2014) and -$270,000 (Q1 2014).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -19.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Galectin Therapeutics 224.13 Mn 167.48 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 -10,000.00
Sep 30, 2014 -53,000.00
Jun 30, 2014 -67,000.00
Mar 31, 2014 -270,000.00
API Access

Galectin Therapeutics Equity Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=equity-income&ticker=GALT&period=max&api_key=YOUR_API_KEY